Ambler, PA – MBF Therapeutics Inc., a leader in the development of next-generation DNA-based immunotherapeutic vaccines, announce that Joseph Connor, DVM has been appointed to the company’s board of directors.

Dr. Connor joins MBF Therapeutics with more than 40 years of experience in the swine industry. Dr. Connor is the founder of Carthage Veterinary Service, LTD. and Professional Swine Management, LLC.  Dr. Connor regularly consults with veterinarians and producers in the U.S., Asia, South America and Europe to bring them new disease management and biosecurity strategies.  He is a featured speaker at many industry programs and has published a wide variety of peer-reviewed articles on swine health, nutrition, and disease.

Dr. Connor obtained his Doctor of Veterinary Medicine in 1976 from the University of Illinois, an M.S. degree in Veterinary Population Medicine from the University of Minnesota in 2006, and completed the Executive Veterinary Program in 2009 at the University of Illinois. He is the past president of the American Association of Swine Practitioners and through which he received the Practitioner of the Year Award in 1995.  In 2004, the University of Minnesota awarded him the Allen D. Leman Science in Practice Award.

“We are pleased to welcome Joe to the board of directors at this important stage in our company’s development,” said MBF Therapeutics CEO Thomas Tillett. “Joe has long been recognized as a key opinion leader in the swine industry and this has been recognized by his selection as an inaugural inductee into the Swine Hall of Fame.” Tillett added, “His expertise is especially valuable now as our current focus includes advancing our next-generation vaccines toward commercialization in the swine market.” 

About MBF Therapeutics
MBF Therapeutics has developed and patented an innovative, proprietary T-Max Precision™ DNA vaccine platform to deliver vaccines mucosally that provide safe, durable, broad cross-protection against diseases of concern to livestock and poultry, with significant translational opportunities in human health. T-Max vaccines elicit precise and robust T cell-mediated effector and memory immune responses in mucosal tissues that rapidly clear viruses to limit disease to the site of infection, block spread in the body, and prevent transmission from the infected animal to other in-contact animals.

For more information about MBF Therapeutics, visit www.mbftherapeutics.com.

Forward-Looking Statements 
This press release contains “forward-looking statements” concerning the development of MBF Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. MBF Therapeutics undertakes no obligation to update any forward-looking statements for any reason.